Abbott Laboratories (ABT) Stock

NYSE
HealthcareMedical Devices Website

ABT has an Alpha Score of 41 out of 100 (weak), computed on Nov 13, 2026 from 3 of 4 sub-scores. 51 members of Congress disclosed 131 trades in ABT since 2014: 69 purchases and 61 sales, most recently Pete Sessions (sale, Oct 2, 2026). 7 of the hedge funds AlphaScala tracks reported ABT in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Millennium Management's at $207.15M. Company insiders reported 0 open-market buys and 4 sales on SEC Form 4 in the 90 days to Nov 20, 2026. Its trailing P/E ratio is 40.5 and its net margin 9.8% (key statistics as of Nov 8, 2026).

$103.00
-0.84%
Last price
Source: Finnhub
Alpha Score
41
Weak

What is ABT's Alpha Score?

How it works →

Alpha Score of 41 reflects weak overall profile with moderate momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
56
Moderate
Value
32
Poor
Quality
45
Weak

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 13, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Abbott Laboratories (ABT)?

Members
51
Disclosed trades
131
Purchases
69
Sales
61

Most recent: Pete Sessions (sale, Oct 2, 2026); records start Jun 10, 2014.

PoliticianTrade dateTypeAmount
Pete Sessions
R-TX · House
2026-10-02sale$50k – $100k
Gil Cisneros
D-CA · House
2026-09-18purchase$1k – $15k
Tom Kean Jr.
R-NJ · House
2026-09-17partial sale$1k – $15k
Rich McCormick
R-GA · House
2026-07-30sale$1k – $15k
Mike Kelly
R-PA · House
2026-07-17sale$1k – $15k
Rick Allen
R-GA · House
2026-07-14sale$15k – $50k
Rick Larsen
D-WA · House
2026-07-08sale$1k – $15k
Gil Cisneros
D-CA · House
2026-06-16purchase$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

Every member of Congress who traded ABT, with filing lags →

Which hedge funds own ABT?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Millennium Management
Israel Englander
2.10M$207.15M-42%
Point72
Steve Cohen
1.84M$181.86M+19%
Citadel
Ken Griffin
1.70M$167.91M-80%
Renaissance Technologies
Jim Simons (founder)
458K$45.31M-33%
Marshall Wace445K$44.02M-92%
D.E. Shaw
David Shaw
363K$35.91M-75%
Bridgewater Associates
Ray Dalio
56K$5.51M-7%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are Abbott Laboratories insiders buying or selling?

SEC Form 4 filings
90 days to Nov 20, 2026
Buys
0
Sells
4
Net $
-$46.6M
Unique insiders
3
DateInsiderRoleTypeSharesValue
Nov 5, 26Moreland Mary KEXECUTIVE VICE PRESIDENTSELL3.5K$406K
Sep 2, 26Mccoy John A. Jr.VICE PRESIDENT AND CONTROLLERSELL27$3K
Aug 25, 26Ford Robert BCHAIRMAN AND CEOSELL218.5K$25.3M
Aug 25, 26Ford Robert BCHAIRMAN AND CEOSELL180.3K$20.9M
Aug 11, 26Morrone Louis H.EXECUTIVE VICE PRESIDENTSELL5.8K$643K
Mar 2, 26Shroff EricSenior Vice PresidentSELL709$82K
Mar 2, 26Salvadori Daniel Gesua SiveEVP AND GROUP PRESIDENTSELL885$102K
Mar 2, 26Morrone Louis H.EXECUTIVE VICE PRESIDENTSELL1.1K$132K

SEC Form 4 filings as of Nov 20, 2026

See cluster-buy signals across all tickers →

What are ABT's key statistics?

P/E Ratio
40.46
EPS (TTM)
2.70
Dividend Yield
1.98%
Beta
0.49
Net Margin
9.75%
ROE
10.52%
Debt / Equity
0.25
52W High
$132.03
52W Low
$81.97

Key statistics as of Nov 8, 2026

How does ABT's valuation compare with the Healthcare sector?

MetricABTHealthcare medianCompanies in median
P/E ratio40.529.1147
Net margin9.75%3.59%223
Return on equity10.52%3.41%255
Dividend yield (payers)1.98%1.37%61

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 22, 2026). P/E excludes loss-making companies.

What did Abbott Laboratories's latest SEC filings say?

Latest 2
8-KMar 23, 2026SEC.gov →

Abbott Laboratories Completes Acquisition of Exact Sciences Corporation for Cash Consideration

On March 23, 2026, Abbott Laboratories finalized its acquisition of Exact Sciences Corporation. The transaction was executed pursuant to the Agreement and Plan of Merger originally dated November 19, 2025. Under the terms of the agreement, a wholly owned subsidiary of Abbott, Badger Merger Sub I, Inc., merged with and into Exact Sciences. As a result of the merger, Exact Sciences now operates as a direct, wholly owned subsidiary of Abbott Laboratories. Shareholders of Exact Sciences common stock received $105.00 in cash for each share held immediately prior to the effective time of the merger, excluding certain shares as defined in the agreement. The filing confirms the completion of the merger and incorporates the original merger agreement and a press release regarding the closing as exhibits.

Material changes
  • ›Abbott Laboratories completed the acquisition of Exact Sciences Corporation on March 23, 2026.
  • ›Exact Sciences is now a direct, wholly owned subsidiary of Abbott Laboratories.
  • ›Exact Sciences shareholders received $105.00 in cash per share of common stock.
  • ›The transaction was executed under the terms of the November 19, 2025, merger agreement.
8-KMar 9, 2026SEC.gov →

Abbott Laboratories Issues $20 Billion in Senior Notes to Fund Exact Sciences Acquisition

On March 9, 2026, Abbott Laboratories completed a public offering of $20 billion in aggregate principal amount of senior notes. The issuance consists of eight series of notes with varying maturities, ranging from floating rate notes due in 2029 to fixed-rate notes maturing as late as 2066. The offering was conducted pursuant to a pricing agreement dated February 23, 2026, with underwriters including Morgan Stanley, Barclays, BofA Securities, and J.P. Morgan Securities. Abbott intends to use the net proceeds from this offering, alongside cash on hand and potential additional borrowings, to finance its previously announced acquisition of Exact Sciences Corporation. The funds are earmarked for the merger consideration, the repayment of certain Exact Sciences indebtedness, transaction-related fees, and general corporate purposes. The notes include a special mandatory redemption provision. If the acquisition of Exact Sciences is not consummated by the specified "End Date" (generally February 17, 2027, or a later agreed-upon date) or if Abbott notifies the trustee that it will not pursue the acquisition, the company is required to redeem the outstanding notes at 101% of their aggregate principal amount, plus accrued and unpaid interest.

Material changes
  • ›Completed $20 billion senior notes offering across eight tranches.
  • ›Proceeds designated for the acquisition of Exact Sciences Corporation.
  • ›Includes special mandatory redemption at 101% if the acquisition fails to close.
  • ›Funds will also cover repayment of Exact Sciences debt and transaction expenses.
  • ›Notes issued under a shelf registration statement effective February 23, 2026.

ABT price chart

Powered by TradingView

What does Abbott Laboratories do?

Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of health care products worldwide. It operates across four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, addressing needs from chronic disease management to acute diagnostics. The company offers generic pharmaceuticals treating conditions such as pancreatic exocrine insufficiency, irritable bowel syndrome, dyslipidemia, hypertension, hypothyroidism, pain, fever, inflammation, and migraine, alongside anti-infectives, influenza vaccines, and gastrointestinal regulators. Notable products include cardiovascular devices like pacemakers and stents, diabetes management tools such as continuous glucose monitors, pediatric and adult nutritional formulas, and advanced diagnostic equipment like immunoassays and point-of-care testing kits. With approximately 114,000 employees and a history dating back to 1888, Abbott Laboratories generates the majority of its sales outside the United States, playing a pivotal role in advancing medical innovation, improving patient outcomes, and supporting global health initiatives through its extensive reach in consumer, institutional, and professional markets.

CEO
Mr. Robert B. Ford
Employees
115,000
Market Cap
$190.22B
Ask about ABTAI research agent